These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8791028)

  • 21. 311C90: patient profiles and typical case histories of migraine management.
    Dowson AJ
    Neurology; 1997 Mar; 48(3 Suppl 3):S29-33. PubMed ID: 9071268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triptans to the rescue: effective therapy for migraine headaches in the workplace.
    Bartleson JD
    Mayo Clin Proc; 2000 Aug; 75(8):780-1. PubMed ID: 10943229
    [No Abstract]   [Full Text] [Related]  

  • 23. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.
    Thomsen LL; Dixon R; Lassen LH; Gibbens M; Langemark M; Bendtsen L; Daugaard D; Olesen J
    Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials.
    Diener HC; Dowson AJ; Ferrari M; Nappi G; Tfelt-Hansen P
    Cephalalgia; 1999 Oct; 19(8):699-700. PubMed ID: 10570722
    [No Abstract]   [Full Text] [Related]  

  • 25. Zolmitriptan for migraine.
    Med Lett Drugs Ther; 1998 Feb; 40(1021):27-8. PubMed ID: 9505961
    [No Abstract]   [Full Text] [Related]  

  • 26. Is a central action of acute antimigraine drugs essential?
    Goadsby PJ
    Cephalalgia; 1997 Jun; 17 Suppl 17():10-1. PubMed ID: 9218879
    [No Abstract]   [Full Text] [Related]  

  • 27. Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action.
    Martin GR
    Eur Neurol; 1996; 36 Suppl 2():13-8. PubMed ID: 8791027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Would any acute treatment for migraine demonstrate recurrence?
    Dahlöf C
    Cephalalgia; 1997 Jun; 17 Suppl 17():17-9; discussion 19-20. PubMed ID: 9218881
    [No Abstract]   [Full Text] [Related]  

  • 29. Spinal cord infarction during use of zolmitriptan: a case report.
    Vijayan N; Peacock JH
    Headache; 2000 Jan; 40(1):57-60. PubMed ID: 10759907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
    Deleu D; Hanssens Y
    Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
    Seaber E; On N; Phillips S; Churchus R; Posner J; Rolan P
    Br J Clin Pharmacol; 1996 Feb; 41(2):141-7. PubMed ID: 8838441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Differentiated therapy of migraine attack].
    Skoromets AA; Amelin AV; Korenko LA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):39. PubMed ID: 10629928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J; Sawyer J
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring central action of acute antimigraine drugs in humans.
    Schoenen J
    Cephalalgia; 1997 Jun; 17 Suppl 17():12-5; discussion 15-6. PubMed ID: 9218880
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy of 5HT in migraine.
    Buzzi MG
    Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
    [No Abstract]   [Full Text] [Related]  

  • 36. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical efficacy of zolmitriptan in migraine].
    Leira R; Noya M
    Neurologia; 1998 Oct; 13 Suppl 2():16-24. PubMed ID: 9859691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
    Geraud G; Olesen J; Pfaffenrath V; Tfelt-Hansen P; Zupping R; Diener HC; Sweet R
    Cephalalgia; 2000 Feb; 20(1):30-8. PubMed ID: 10817444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.